Book a Call Today

Next-Generation Sequencing Market Forecast 2035 | Short-Read, Long-Read, Single-Cell & Spatial Sequencing Platforms for Oncology, Rare Disease, Infectious Disease, Genomics Research & Clinical Diagnostics

Next-generation sequencing has transformed genomics from a research tool into a clinical diagnostic standard, enabling whole genome sequencing, targeted panel testing, RNA-seq, and single-cell genomics at speeds and costs orders of magnitude below first-generation Sanger sequencing. The global next-generation sequencing market is projected to reach USD 42.1 billion by 2035 at a 16.9% CAGR, driven by clinical oncology NGS adoption for tumour profiling and liquid biopsy, long-read sequencing platforms from Oxford Nanopore and Pacific Biosciences achieving clinical grade accuracy, and single-cell and spatial sequencing expanding NGS applications into cell-type resolution biological discovery.

The NGS market is at a competitive inflection point as Oxford Nanopore Technologies, Pacific Biosciences HiFi, and new entrants Element Biosciences, Ultima Genomics, and MGI Tech challenge Illumina’s dominant short-read sequencing position. Long-read sequencing from Oxford Nanopore and Pacific Biosciences is resolving structural variants, repetitive regions, and full-length transcript isoforms inaccessible to short-read platforms, driving adoption in clinical rare disease diagnosis, pharmacogenomics, and infectious disease applications.

Executive Snapshot

What is next-generation sequencing?
Next-generation sequencing (NGS) is massively parallel DNA and RNA sequencing technology generating millions to billions of sequence reads simultaneously, enabling whole genome, exome, transcriptome, and epigenome sequencing at throughput and cost levels making genomics accessible for clinical diagnostics, population research, and routine biological discovery.

What is driving NGS market growth?
Clinical oncology NGS adoption for comprehensive tumour profiling and liquid biopsy ctDNA detection; long-read sequencing clinical grade accuracy enabling structural variant and pharmacogenomics applications; single-cell sequencing expanding into clinical and translational research; and sequencing cost declines enabling large-scale population genomics programmes.

What are the main NGS application areas?
Clinical oncology — solid tumour and haematological malignancy profiling, liquid biopsy; rare disease diagnosis — WGS and WES for undiagnosed genetic conditions; infectious disease surveillance and outbreak genomics; population genomics research; single-cell and spatial transcriptomics; and reproductive genetics.

How does long-read sequencing differ from short-read NGS?
Short-read NGS (Illumina) generates 150–300 bp reads with high accuracy (>99.9%) and low cost; long-read sequencing from Oxford Nanopore and Pacific Biosciences HiFi generates reads of 10 kb–10 Mb, resolving structural variants, phasing haplotypes, and sequencing repetitive regions and full-length mRNA transcripts inaccessible to short-read assembly.

Which regions lead the NGS market?
North America leads with 42%+ of global NGS revenue driven by clinical laboratory and biopharma adoption; Europe is the second-largest market; Asia-Pacific is the fastest-growing NGS market driven by BGI, MGI Tech, and national genomic medicine investment in China, Japan, and Singapore.

What does the NGS market look like in 2035?
Whole genome sequencing cost falls below USD 100 enabling universal newborn WGS; long-read and short-read sequencing converge on a single clinical standard; single-cell and spatial sequencing are routine in translational medicine; and real-time nanopore sequencing is standard in infectious disease surveillance and point-of-care diagnostics.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Next-Generation Sequencing Market

The structural forces reshaping this market — what researchers, biopharma companies, technology vendors, and investors must understand.

  • Clinical Oncology NGS Adoption for Comprehensive Tumour Profiling and Liquid Biopsy Driving Revenue Growth: Comprehensive genomic profiling of solid tumours by Foundation Medicine, Guardant Health, and Tempus and liquid biopsy ctDNA panels for treatment monitoring are driving clinical oncology NGS adoption as oncologists use NGS-based companion diagnostics to select targeted therapies, monitor treatment response, and detect early resistance mutations in solid tumour and haematological malignancy patients.
  • Long-Read Sequencing Clinical Grade Accuracy Enabling Structural Variant and Pharmacogenomics Applications: Oxford Nanopore Q20+ accuracy and Pacific Biosciences HiFi >99.9% long-read accuracy are enabling clinical long-read sequencing applications in structural variant detection for rare disease, CYP2D6 pharmacogenomics haplotyping, HLA typing, and repeat expansion disorder diagnosis previously inaccessible to short-read assembly.
  • Single-Cell and Spatial Transcriptomics Expanding NGS into Cell-Type Resolution Biological Discovery: 10x Genomics Chromium single-cell RNA-seq, Visium spatial transcriptomics, and Xenium in situ sequencing are driving single-cell and spatial NGS adoption as researchers map cell type heterogeneity in tumour microenvironments, developmental biology, and neuroscience at single-cell and spatial resolution.
  • New Sequencing Platform Entrants Challenging Illumina Short-Read Dominance and Driving Price Competition: Element Biosciences AVITI, Ultima Genomics UG 100, and MGI Tech DNBSEQ platforms offering Illumina-comparable short-read accuracy at 20–40% lower cost per sample are creating NGS sequencing platform price competition as customers benchmark alternative platforms against Illumina NovaSeq for large-scale WGS, RNA-seq, and population genomics workloads.
  • Infectious Disease Genomics and Pandemic Preparedness Driving Real-Time NGS Surveillance Adoption: COVID-19 pandemic demonstrating real-time nanopore sequencing for SARS-CoV-2 variant surveillance has driven infectious disease NGS surveillance adoption as public health agencies invest in NGS-based pathogen genomic surveillance infrastructure for influenza, respiratory viruses, and AMR pathogen tracking using Oxford Nanopore rapid sequencing platforms.
  • Population Genomics Programmes Generating 100 Million+ WGS Genomes Driving NGS Throughput Demand: UK Biobank 500,000 WGS, US All of Us 1 million WGS, and national population genomics programmes in Finland, Estonia, Iceland, and China are driving population-scale WGS NGS demand requiring Illumina NovaSeq X, BGI DNBSEQ, and high-throughput NGS platforms capable of generating thousands of clinical-grade WGS per day.

Market Segmentation: Next-Generation Sequencing Market

By Product
  • Products
    • Consumables
      • Library Prep Kits & Reagents
      • Sequencing Kits & Reagents
      • Others
    • Platforms
      • Sequencing Platforms
      • Library Preparation Platforms
    • Bioinformatic Tools
      • Data Analysis Software & Workbenches
      • Data Visualization Tools
      • Others
  • Services
    • Presequencing Services
      • Sample Preparation / Isolation
      • Library Preparation and Target Enrichment
      • Quality Control
    • Sequencing Services
      • Exome & Targeted Resequencing and Custom Panels
      • RNA Sequencing
      • DE NOVO Sequencing
      • Chip Sequencing
      • Whole Genome Sequencing
      • Methyl Sequencing
      • Others
    • Bioinformatics & Data Analysis Services
      • Data Analysis Services
      • Data Visualization & Interpretation
      • Data Storage & Management Services
    • Services for NGS Platform
By Application
  • Oncology
    • Diagnostics and Screening
      • Oncology Screening
        • Sporadic Cancer
        • Inherited Cancer
      • Companion Diagnostics
      • Other Diagnostics
    • Research Studies
  • Clinical Investigation
    • Infectious Diseases
    • Inherited Diseases
    • Idiopathic Diseases
    • Non-Communicable/Other Diseases
  • Reproductive Health
    • NIPT
      • Aneuploidy
      • Microdeletions
    • PGT
    • Newborn Genetic Screening
    • Single Gene Analysis
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Others
By Workflow
  • Pre-Sequencing
    • Nucleic Acid Extraction
    • Library Preparation
  • Sequencing
  • NGS Data Analysis
    • NGS Primary Data Analysis
    • NGS Secondary Data Analysis
    • NGS Tertiary Data Analysis
By End User
  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other Users
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, 
    Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Next-Generation Sequencing Market

  1. Clinical Oncology NGS Adoption for Comprehensive Tumour Profiling and Liquid Biopsy Driving Revenue Growth: Comprehensive genomic profiling by Foundation Medicine, Guardant Health, and Tempus and liquid biopsy ctDNA panels for treatment monitoring are driving clinical oncology NGS adoption as oncologists use NGS-based companion diagnostics to select targeted therapies and monitor treatment response.
  2. Long-Read Sequencing Clinical Grade Accuracy Enabling Structural Variant, Pharmacogenomics, and HLA Typing: Oxford Nanopore Q20+ and Pacific Biosciences HiFi >99.9% long-read accuracy enable clinical long-read sequencing applications in structural variant detection, CYP2D6 pharmacogenomics haplotyping, HLA typing, and repeat expansion disorder diagnosis.
  3. Single-Cell and Spatial Transcriptomics Expanding NGS into Cell-Type Resolution Biological Discovery: 10x Genomics Chromium single-cell RNA-seq and Visium spatial transcriptomics drive single-cell and spatial NGS adoption as researchers map cell type heterogeneity in tumour microenvironments, developmental biology, and neuroscience.
  4. New Sequencing Platform Entrants Challenging Illumina and Driving 20–40% Price Reduction in Short-Read WGS: Element Biosciences AVITI, Ultima Genomics UG 100, and MGI Tech DNBSEQ offering comparable accuracy at 20–40% lower cost create NGS sequencing platform price competition for large-scale WGS, RNA-seq, and population genomics workloads.
  5. Infectious Disease NGS Surveillance and Pandemic Preparedness Driving Real-Time Nanopore Sequencing Adoption: COVID-19 pandemic demonstrating real-time nanopore sequencing for variant surveillance drives infectious disease NGS surveillance adoption as public health agencies invest in NGS-based pathogen genomic surveillance for influenza, respiratory viruses, and AMR pathogen tracking.
  6. Population Genomics Programmes Generating 100 Million+ WGS Genomes Driving NGS Throughput Investment: UK Biobank, US All of Us, and national population genomics programmes generating 500,000–1 million WGS per programme drive population-scale NGS throughput demand requiring Illumina NovaSeq X and BGI DNBSEQ high-throughput sequencing capacity.

Regional Outlook: Next-Generation Sequencing Market

Competitive Landscape: Next-Generation Sequencing Market

Next-Generation Sequencing Market Forecast 2035 — Key Industry Participants

  • Short-Read NGS Platform Vendors: Illumina, MGI Tech, Element Biosciences, and Ultima Genomics are the leading short-read NGS platform vendors competing on sequencing throughput, data quality, cost per genome, instrument footprint, and platform compatibility with established library preparation and bioinformatics pipelines.
  • Long-Read NGS Platform Vendors: Pacific Biosciences, Oxford Nanopore Technologies, and Illumina, and Loop Genomics are the leading long-read NGS platform vendors competing on read length, accuracy, throughput, cost per sample, and ability to resolve structural variants, phased haplotypes, and full-length transcript isoforms.
  • NGS Library Preparation and Enrichment Vendors: Thermo Fisher Scientific, New England Biolabs, QIAGEN, and Integrated DNA Technologies (IDT) are the leading NGS library preparation and target enrichment vendors competing on library preparation kit automation compatibility, adapter ligation efficiency, target capture panel coverage, and ultra-low-input library preparation for cfDNA and single-cell NGS applications.
  • Single-Cell and Spatial Sequencing Platform Vendors: 10x Genomics, NanoString, Vizgen, and Resolve Biosciences are the leading single-cell and spatial sequencing platform vendors competing on single-cell capture throughput, cell doublet rate, spatial resolution, multiplexing capability, and tissue processing compatibility.
  • NGS Bioinformatics and Clinical Reporting Platforms: Sentieon, and TileDB are the leading NGS bioinformatics and data analysis platform vendors competing on variant calling pipeline speed and accuracy, ACMG variant annotation, cloud-scale genomic data management, and clinical report generation for oncology and rare disease NGS applications.
  • Clinical Oncology NGS Service and CDx Providers: Foundation Medicine, Guardant Health, Tempus, and Caris Life Sciences are the leading clinical oncology NGS service and companion diagnostic providers competing on comprehensive genomic profiling panel gene count, liquid biopsy ctDNA sensitivity, turnaround time, and payer reimbursement coverage for companion diagnostic indications.
  • NGS Sequencing-as-a-Service Providers: BGI Genomics, Novogene, Azenta Life Sciences, and Macrogen are the leading NGS sequencing-as-a-service providers competing on WGS, RNA-seq, and single-cell NGS service price per sample, throughput capacity, data quality, and bioinformatics pipeline deliverable completeness.

Consultant POV

“NGS is the platform that made precision medicine possible. The next decade will be defined by two transitions: long-read sequencing achieving clinical grade accuracy at clinical grade cost, and single-cell sequencing moving from research into clinical routine. The company that solves the clinical long-read problem — clinical accuracy, clinical cost, clinical workflow integration — will redefine molecular diagnostics. Oxford Nanopore is closest. Pacific Biosciences HiFi is already there on accuracy. Cost is the remaining barrier.”

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report